Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REKHA JOHN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1619979846
CMS profile
118220
Location
KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$388.84

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $387.18 14
Education $1.66 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REKHA JOHN

NPI 1619979846 · CMS profile ID 118220

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
REKHA JOHN, NPI 1619979846, CMS profile ID 118220, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $388.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $30.3312/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200259903 CMS
Travere Therapeutics, Inc. $19.8511/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244437951 CMS
Novo Nordisk Inc $26.2910/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188408084 CMS
Novartis Pharmaceuticals Corporation $18.8210/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200359250 CMS
SHIELD THERAPEUTICS INC $15.0210/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249627224 CMS
Travere Therapeutics, Inc. $1.6610/14/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1244437949 CMS
Alexion Pharmaceuticals, Inc. $19.7109/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202913308 CMS
Calliditas Therapeutics US Inc. $27.0208/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234998663 CMS
Amgen Inc. $23.4707/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228507615 CMS
Novartis Pharmaceuticals Corporation $32.2607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200359238 CMS
Amgen Inc. $24.8906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228507617 CMS
Fresenius USA Marketing, Inc. $18.4006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244819341 CMS
CorVista Health, Inc. $93.8104/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250325732 CMS
Amgen Inc. $13.7204/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227176924 CMS
Calliditas Therapeutics US Inc. $23.5904/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234998661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $77.93 6
PY2020 $119.67 2
PY2022 $404.00 18
PY2023 $539.51 20
PY2024 $2,789.07 18
PY2025 $388.84 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,069.81 26
PY2024 Principal investigator $549,482.70 50
PY2023 Principal investigator $376,752.37 57
PY2022 Recipient $7,645.61 7
PY2022 Principal investigator $353,881.30 372
PY2021 Principal investigator $168,644.86 191
PY2020 Principal investigator $154,822.49 45
PY2019 Principal investigator $231,281.89 292

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,150.00 12/21/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287197
Principal investigator 1 AKEBIA THERAPEUTICS INC $974.70 12/16/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287109
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,966.00 12/11/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287037
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,966.00 12/11/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287039
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 12/10/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753287017
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $25,934.47 10/23/2020 Non-covered Recipient Entity
FRENOVA MEDICAL CARE
PHASE 3B, RANDOMIZED, OPEN-LABEL, SPONSOR-BLIND, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT, ONCE DAILY (QD) AND THREE TIMES WEEKLY (TIW) FOR THE MAINTENANCE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) No dispute reported 06/30/2026 748805769
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 10/12/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286555
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 10/12/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286559
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 09/09/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286343
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 09/09/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286345
Principal investigator 1 AKEBIA THERAPEUTICS INC $891.00 08/14/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286137
Principal investigator 1 AKEBIA THERAPEUTICS INC $891.00 08/14/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286161
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,041.00 07/23/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285907
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,741.00 07/23/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285913
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,161.08 07/13/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285679
Principal investigator 1 AKEBIA THERAPEUTICS INC $390.00 07/07/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285363
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,676.00 07/01/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285081
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,491.00 06/16/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284749
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,491.00 06/16/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284769
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,491.00 06/15/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284733
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,491.00 06/15/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284735
Principal investigator 1 AKEBIA THERAPEUTICS INC $463.60 06/02/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284273
Principal investigator 1 Gilead Sciences, Inc. $8,500.00 05/27/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742090883
Principal investigator 1 AKEBIA THERAPEUTICS INC $463.60 05/11/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283729
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,342.10 05/06/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283459
Principal investigator 1 AKEBIA THERAPEUTICS INC $14.20 05/06/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753283607
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,816.00 05/04/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283301
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,446.00 05/04/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283303
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,024.10 04/01/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282631
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,932.55 04/01/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282635
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,141.30 03/18/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282287
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,791.00 03/16/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282105
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,183.10 03/16/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282139
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,574.15 03/02/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753281735
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,250.00 02/25/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289541
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,017.80 02/24/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289203
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,000.00 02/18/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289081
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,441.00 02/12/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288835
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,636.10 02/12/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288843
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,664.40 02/03/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288289
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,848.80 02/03/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288295
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,343.24 01/15/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753287915
Principal investigator 1 AKEBIA THERAPEUTICS INC $29,496.75 01/08/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753285945
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,782.95 01/02/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286641
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,639.50 01/02/2020 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287277